The Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Relapsed Ectopic Male Breast Cancer

被引:1
作者
Baek, Dong Won [1 ]
Park, Jee Young [2 ]
Lee, Soo Jung [1 ]
Chae, Yee Soo [1 ]
机构
[1] Kyungpook Natl Univ, Canc Res Inst, Dept Oncol Hematol, Chilgok Hosp,Sch Med, 807 Hoguk Ro, Daegu 41404, South Korea
[2] Kyungpook Natl Univ, Canc Res Inst, Dept Pathol, Chilgok Hosp,Sch Med, 807 Hoguk Ro, Daegu 41404, South Korea
关键词
Breast neoplasms; Male; Palbociclib; PALBOCICLIB; LETROZOLE;
D O I
10.4048/jbc.2020.23.e39
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ectopic male breast cancer is very rare. Consequently, there is a lack of prospective clinical trials, and most recommendations for treatment are based on the experiences of clinicians and data from female breast cancer patients. The United States Food and Drug Administration has recently approved palbociclib combined with endocrine therapy for advanced male breast cancer because of the positive results of its use in metastatic female breast cancer. Therefore, it is worth considering cyclin-dependent kinase 4/6 inhibitors as alternatives to conventional chemotherapies for advanced male breast cancer patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative cancers. The present case report introduces the use of palbociclib plus letrozole as first-line therapy for an elderly male patient with relapsed ectopic breast cancer, notwithstanding the limitations of the current national health insurance policy.
引用
收藏
页码:560 / 566
页数:7
相关论文
共 50 条
  • [41] A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer
    Zhang, Jialin
    Xu, Xinyu
    Zhou, Yeyue
    Su, Jingyang
    Wang, Jue
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [42] Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors
    Gomatou, Georgia
    Trontzas, Ioannis
    Ioannou, Stephanie
    Drizou, Maria
    Syrigos, Nikolaos
    Kotteas, Elias
    MOLECULAR BIOLOGY REPORTS, 2021, 48 (01) : 915 - 925
  • [43] Does toxicity of cyclin-dependent kinase 4/6 inhibitor predict treatment response in metastatic hormone-positive breast cancer patients?
    Gulbagci, Burcu
    Demirci, Ayse
    Celebi, Abdussamet
    Firat, Sedat Tarik
    Gokmen, Ivo
    Ugurlu, Irem
    Ilce, Huri Tilla
    Cakir, Emre
    Hacibekiroglu, Ilhan
    ONCOLOGY IN CLINICAL PRACTICE, 2025,
  • [44] Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors
    Ettl, Johannes
    BREAST CARE, 2019, 14 (02) : 86 - 92
  • [45] Cyclin-dependent kinase 4/6 inhibitor in combination with endocrine therapy versus endocrine therapy only for advanced breast cancer: a systematic review and meta-analysis
    Xu, Zhi-Hong
    Zhang, Heng
    Wei, Deng-Hui
    Xie, Li-Li
    Xu, Chun-Sen
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 657 - 668
  • [46] The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC)
    Eiger, Daniel
    Wagner, Marcio
    Ponde, Noam F.
    Nogueira, Melanie S.
    Buisseret, Laurence
    de Azambuja, Evandro
    ACTA ONCOLOGICA, 2020, 59 (06) : 723 - 725
  • [47] Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers
    Hur, Saem
    Kim, Ju Hee
    Yun, Jihui
    Ju, Young Wook
    Han, Jong Min
    Heo, Woohang
    Kim, Kwangsoo
    Jeong, Kyeonghun
    Lee, Han-Byoel
    Han, Wonshik
    Noh, Dong-Young
    Hong, Dongwan
    Moon, Hyeong-Gon
    JOURNAL OF BREAST CANCER, 2020, 23 (02) : 162 - 170
  • [48] Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies
    Kwapisz, Dorota
    BREAST CANCER, 2018, 25 (05) : 506 - 516
  • [49] Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Quantum Leap in the Treatment of Advanced Breast Cancers
    Reddy, Sanjana
    Barkhane, Zineb
    Elmadi, Jalal
    Kumar, Lakshmi Satish
    Pugalenthi, Lakshmi Sree
    Ahmad, Mahlika
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (04)
  • [50] Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis
    Shohdy, Kyrillus S.
    Lasheen, Shaimaa
    Kassem, Loay
    Abdel-Rahman, Omar
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2017, 8 (11) : 337 - 347